JOINN Laboratories

JOINN Laboratories IND Regulatory Filing Services

As a leading CRO in China’s pharmaceutical industry with years of deep expertise in IND regulatory filings, JOINN Laboratories houses a specialized regulatory technical team and extensive filing experience. We maintain full mastery of laws, regulations and technical guidelines issued by NMPA (China), FDA (US), PMDA (Japan), MFDS (South Korea) and OECD (EU).

We deliver end-to-end IND regulatory filing services for NMPA, covering filing strategy planning, Pre-IND meetings, dossier drafting & review, and submission & follow-up. Our service scope spans CMC, non-clinical and clinical disciplines. Backed by over 1,000 successful IND filings, efficient project management and precise regulatory interpretation, we support domestic and global innovative pharmaceutical enterprises in shortening filing timelines, cutting R&D costs, securing IND approvals smoothly and accelerating clinical trial initiation.

IND Regulatory Filing Services

IND (Investigational New Drug) refers to an application for clinical trial authorization of an investigational medicinal product. It marks a critical milestone in drug R&D. The core objective is to submit complete, regulatory-compliant dossiers to drug authorities to demonstrate the safety and rationality of the candidate drug for clinical trials. Only upon approval can all phases of clinical trials be officially launched. Serving as the vital bridge linking non-clinical and clinical research, IND filing directly determines the timeline and success rate of new drug development.

For innovative drug developers, the IND filing workflow is complex with stringent regulatory requirements involving CMC, non-clinical and clinical modules. Filing teams must demonstrate robust regulatory interpretation capabilities, professional dossier writing proficiency and efficient project management. Engaging a specialized CRO effectively mitigates filing risks, shortens review cycles and delivers substantial savings on R&D time and costs.

With years of technical accumulation and industry experience as a pharmaceutical CRO, JOINN Laboratories has built a comprehensive, standardized IND regulatory filing service system, making us a trusted IND filing partner for domestic and global biotech and pharma companies. Our team consists of senior regulatory specialists, CMC experts, toxicologists and clinical professionals equipped with sharp regulatory insights and streamlined filing execution capabilities. Supported by a mature project management framework, standardized dossier drafting workflows and abundant filing track records, we have delivered more than 1,000 successful IND filing projects covering small molecules, biological products and other modalities. We help numerous clients obtain IND approvals to expedite new drug development, demonstrating our industry-leading technical strength and service quality.

Core Service Offerings

I. Non-Clinical Services
Non-clinical research serves as the fundamental backbone of IND filings. Through a series of pharmacology, toxicology and pharmacokinetic studies, researchers characterize the pharmacodynamic effects, safety profiles and in vivo metabolic properties of candidate drugs, generating scientific evidence to support clinical trial initiation. Non-clinical data constitutes the primary basis for drug authorities to assess the feasibility of clinical investigation.

JOINN Laboratories operates a fully integrated non-clinical research platform staffed by specialized scientists conducting all studies in strict GLP compliance, with trial designs aligned with global regulatory authority guidelines. We provide full-spectrum non-clinical research and dossier writing services to ensure accurate, regulatory-compliant and valid non-clinical datasets.

• Pharmacodynamic Studies: Design scientifically sound pharmacodynamic protocols tailored to drug targets and indications; conduct efficacy evaluations across multiple animal models to systematically characterize drug potency, mechanisms of action and dose-effect relationships, generating non-clinical evidence to support clinical efficacy claims.

• Pharmacokinetics (PK) & ADME Studies: Perform systematic absorption, distribution, metabolism and excretion (ADME) testing; accurately quantify in vivo drug concentrations in animals, calculate key PK parameters and delineate metabolic profiles to inform clinical dosing regimen design.

• Safety Pharmacology & Toxicology Evaluation: Conduct comprehensive safety testing including acute toxicity, repeat-dose toxicity, reproductive toxicity and genotoxicity in full GLP compliance. Systematically characterize potential toxic risks and define safe dose ranges to underpin clinical safety.

• Bioanalysis: Deploy state-of-the-art analytical platforms such as LC-MS/MS to establish accurate, sensitive bioanalytical methods for quantitation of drug concentrations and identification of metabolites, ensuring high-fidelity non-clinical data to support regulatory dossiers.

• Non-Clinical Overviews & Tabulated Summaries: Compose specialized non-clinical overviews and tabulated summaries that organize all non-clinical data and findings in full alignment with regulatory formatting standards to streamline authority review.

II. Clinical Services
Our clinical service module focuses on preparing and optimizing clinical documentation required for IND filings. We develop science-driven clinical development strategies aligned with product attributes and R&D milestones, drafting clinical regulatory documents compliant with authority standards to deliver scientifically robust, risk-mitigated clinical trial designs critical to successful IND clearance. Our team of senior clinical specialists brings deep expertise in clinical protocol design and dossier composition to tailor clinical documentation for all drug modalities and streamline client dossier preparation.

• Clinical Protocol & Development Strategy Design: Formulate rational clinical development roadmaps and detailed clinical trial protocols incorporating indication-specific profiles, pharmacodynamic outputs and non-clinical safety data. Clearly define trial objectives, study populations, dosing regimens and evaluation endpoints to deliver scientifically rigorous, compliant and efficient clinical programs.

• Investigator’s Brochure (IB) Writing: Compile comprehensive Investigator’s Brochures per regulatory requirements, consolidating all CMC, non-clinical and pre-clinical data to provide trial investigators with full product information and support safe, orderly clinical trial conduct.

• Informed Consent Form (ICF) Drafting: Develop ethics and regulation-compliant informed consent forms aligned with trial protocols, clearly communicating trial objectives, study procedures, potential risks and benefits to subjects to protect participant rights while satisfying filing standards.

• Risk Management Plan (RMP) Compilation: Develop robust Risk Management Plans addressing all identified drug safety hazards, outlining frameworks for risk identification, assessment, mitigation and post-trial monitoring to ensure controllable clinical risks and meet regulatory submission criteria.

• Clinical Overviews & Summaries: Draft formal clinical overviews and consolidated summaries that synthesize background information, research datasets and conclusions, providing comprehensive clinical justification for IND review by regulatory authorities.

III. Core Regulatory Filing Services
Regulatory filing execution serves as the coordinating and delivery hub of the entire IND program. We create customized filing strategies tailored to client needs and product characteristics, coordinate cross-module dossier preparation, conduct Pre-IND meeting support, draft, review and submit full IND dossiers, track review progress throughout the process, and promptly respond to authority questions to drive efficient review and successful IND approval. Drawing on extensive filing experience and established communication channels with regulatory bodies, we deliver end-to-end regulatory services to minimize overall review timelines.

• Regulatory Filing Strategy Analysis & Regulatory Consulting: Conduct holistic regulatory interpretation and filing roadmap analysis based on product modality and R&D stage, deliver customized submission recommendations outlining filing priorities, workflows and risk mitigation measures to eliminate regulatory pitfalls.

• Pre-IND Meeting Dossier Preparation & Submission: Support clients in drafting Pre-IND briefing documents, consolidate core questions and development concerns for regulatory authorities, coordinate meeting logistics and facilitate productive dialogue with review experts to incorporate official feedback and optimize full IND dossiers prior to formal submission.

• IND Dossier (M1–M5) Drafting, Review & Submission: Compile and audit complete IND dossiers (M1–M5) in strict adherence to regulatory formatting standards, integrating consolidated documentation from CMC, non-clinical and clinical streams to guarantee fully complete, compliant and gap-free submissions.

Core Technical Advantages

Leading Regulatory Interpretation Capabilities

Our team of senior regulatory specialists maintains comprehensive expertise over laws, technical guidelines and review standards from NMPA, FDA, PMDA, MFDS and OECD. We deliver compliant, specialized filing strategy advice based on up-to-date regulatory updates to help clients avoid regulatory non-compliance risks.

1. Extensive Filing Track Record

We have completed over 1,000 successful IND filings across small molecules, biological products and diverse modalities. Our deep repository of case experience equips us to anticipate modality-specific filing challenges and resolve submission hurdles efficiently, raising overall approval success rates.

2. Integrated End-to-End Service

Our full-spectrum IND filing service covers the entire lifecycle: strategy design, cross-discipline dossier drafting and review, Pre-IND meeting coordination, dossier submission and post-submission review follow-up. The one-stop solution eliminates the need for clients to coordinate multiple vendors, drastically boosting submission efficiency and cutting client time and labor costs.

3. Specialized Cross-Disciplinary Team Support

Our integrated team comprises regulatory, CMC, toxicology, clinical and medical writing specialists with clear role delineation and cross-functional collaboration, ensuring exceptional professionalism and precision across all deliverables and high-quality regulatory dossiers.

4. Efficient Project Management & Global Filing Capacity

A mature project management system assigns dedicated project managers to track all filing milestones, provide real-time progress updates and rapidly address client inquiries and official review comments to accelerate IND timelines. We support parallel NMPA and FDA dual-track filings and possess full familiarity with submission workflows of major global regulators, delivering international IND services to facilitate clients’ global market expansion.

Success Cases

Case Study: NMPA IND Filing for an Innovative Small Molecule Drug

The client entrusted JOINN Laboratories with full-service IND filing covering CMC, non-clinical and clinical dossier drafting and regulatory submission. We developed a customized filing strategy based on product attributes and assigned a dedicated cross-functional project team. Our scope included API and finished dosage form quality characterization, full non-clinical safety evaluation and clinical trial protocol design, alongside precise compilation of the complete M1–M5 IND dossier. We supported the client throughout the Pre-IND consultation phase and promptly addressed all official review queries. The project secured NMPA IND approval expeditiously with no outstanding pre-clinical remediation requirements stipulated in the approval letter, enabling immediate clinical trial initiation, substantially shortening the client’s R&D timeline and earning full client recognition.

Frequently Asked Questions (FAQ)

Q1: What are the core workflows and requirements for IND regulatory filings?

The IND filing workflow consists of an optional preliminary procedure and mandatory formal steps: 1. Optional Step: Pre-IND Meeting – Draft and submit Pre-IND briefing documents to regulators, host consultation meetings to obtain expert review feedback and optimize the full IND dossier. 2. Mandatory Steps: Compile full IND dossiers (covering CMC, non-clinical and clinical modules) → File IND application → Administrative formality check by regulators → Specialized scientific review (pharmacology/toxicology, clinical, CMC, statistics, etc.) → Final decision issued within 30 / 60 working days (approval, disapproval or clinical hold). If deficiencies are identified, revised dossiers must be resubmitted to lift the clinical hold or secure approval before trial initiation. Notes: FDA operates a 30-day review timeline; NMPA standard review duration is 60 working days, with a 30-day fast-track pathway available for rare disease therapies and global simultaneous development programs. NMPA adopts a tacit approval system for IND applications. Core Requirements: All submitted dossiers must be complete, regulatory-compliant and data-supported, encompassing three core modules: ① CMC: API manufacturing, formulation development, quality control and stability studies ② Non-clinical Research: Pharmacology, pharmacokinetics and toxicology test data ③ Clinical Documentation: Clinical trial protocols, Investigator’s Brochure, Risk Management Plan, etc. JOINN Laboratories provides full lifecycle support to align all workflows and satisfy regulatory criteria for seamless filings.

Q2: What is the value of a Pre-IND meeting? Is it compulsory?

Pre-IND consultation meetings enable biopharma sponsors to engage directly with regulatory reviewers prior to formal IND submission. The dialogue clarifies dossier priorities, technical bottlenecks and potential gaps, delivers official review guidance to refine submission materials, reduces filing deficiencies, improves IND approval odds and shortens overall review cycles. Pre-IND meetings are not a mandatory procedural step. However, they are strongly recommended for novel chemical entities and complex formulations with elevated filing complexity to mitigate regulatory risks. JOINN Laboratories supports clients in drafting briefing documents, coordinating meeting logistics and tracking post-meeting follow-up to maximize the value of regulatory consultation.

Q3: What specific content is included in NMPA IND dossiers (M1–M5)?

Breakdown of the M1–M5 IND dossier structure for China NMPA: ① M1 (Administrative Information & Product Data): Cover letter, application form, enterprise qualification certificates, draft product labeling, clinical trial plan and protocols, Investigator’s Brochure, informed consent forms and Risk Management Plan. ② M2 (CTD Summaries): CTD introduction, quality overall summary, non-clinical overall summary, clinical overall summary, tabulated non-clinical summaries and clinical consolidated summaries. ③ M3 (Quality Module): Raw material, finished dosage form, appendices and region-specific quality documentation. ④ M4 (Non-Clinical Study Reports): All pharmacology, pharmacokinetic and toxicology study reports plus reference literature. ⑤ M5 (Clinical Study Documentation): Inventory of all clinical studies, clinical trial reports and reference literature.

Q4: Which jurisdictions does JOINN Laboratories support for IND filings?

Our core offering covers NMPA (China) IND filings. We additionally provide submission support and regulatory consulting services for FDA (US), PMDA (Japan), MFDS (South Korea) and EU competent authorities. Our international regulatory team maintains full expertise over jurisdiction-specific laws and technical guidance, supporting standalone regional filings or parallel multi-jurisdiction programs. We possess extensive experience in synchronized NMPA and FDA dual-track filings to accelerate global development and international market access for clients.

Q5: What is the typical IND filing timeline, and how does JOINN Laboratories accelerate review schedules?

Total timelines vary by jurisdiction, product modality and dossier readiness: ① NMPA IND: 2–4 months for dossier preparation + standard 60 working days of official review ② FDA IND: 2–5 months for dossier preparation + 30-day review window JOINN Laboratories shortens overall development timelines through three core measures: 1. Leverage our database of 1,000+ successful filings to design customized submission strategies and streamline dossier drafting workflows 2. Deploy dedicated cross-functional teams to enable parallel drafting and cross-module review, improving documentation efficiency 3. Maintain close communication channels with regulators to rapidly address review queries and prevent timeline extensions caused by dossier deficiencies.

Q6: What are the key differences between IND filings for small molecules versus biological products?

Distinctions primarily manifest in CMC, non-clinical and clinical module focus and regulatory expectations: ① CMC Module: Small molecules emphasize API synthetic routes, formulation optimization and quality control specifications; biological products prioritize expression systems, purification workflows, stability characterization and immunogenicity assessment. ② Non-Clinical Module: Biological products require additional dedicated immunogenicity and immunotoxicity testing, while small molecule programs focus on metabolite characterization and long-term toxicology evaluation. ③ Clinical Module: Clinical trial protocols for biologics must integrate immunogenicity monitoring and refined dose-escalation design, whereas small molecule studies center on dosing regimen optimization and adverse event surveillance. JOINN Laboratories has accumulated modality-specific filing experience to deliver tailored submission services matching the unique regulatory demands of each drug class.

Q7: What are the most common causes of IND filing rejection or extended review timelines, and how can these risks be avoided?

Four primary root causes for filing delays or non-approval outcomes: 1. Incomplete, insufficient or format-noncompliant regulatory dossiers 2. Substandard non-clinical datasets, including inadequate safety characterization or undefined PK parameters 3. Scientifically flawed clinical trial design or incomplete risk control frameworks 4. Outdated regulatory interpretation and failure to align submissions with latest guidance documents Mitigation strategies deployed by JOINN Laboratories across all project phases:1. Conduct upfront regulatory landscape analysis and customized filing strategy design to guarantee full regulatory alignment of all deliverables, 2.Perform rigorous cross-checks on all non-clinical and clinical source data to validate accuracy and integrity, 3.Refine clinical trial protocols and fully elaborate Risk Management Plans prior to submission, 4. Assign dedicated project managers to track every filing milestone and resolve emerging roadblocks proactively, minimizing risks of rejection or extended review periods.

Q8: What constitutes JOINN Laboratories’ core competitiveness in IND filing services?

Our competitive advantages fall into five key categories:1.gulatory Expertise: A senior regulatory team delivering precise interpretation of global authority guidance to mitigate compliance risks, 2.Proven Track Record: Over 1,000 successful IND approvals across diverse modalities with deep insights into common filing bottlenecks, 3.End-to-End Integrated Service: Full-lifecycle support spanning strategy design through post-submission review follow-up to maximize submission efficiency, 4.Specialized Multidisciplinary Team: Cross-functional specialists collaborating to deliver high-standard, precise regulatory documentation.

IND